Fludarabine
Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged
Children's Oncology GroupSmall moleculePhase 2Active
CCC
53/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 38/ 100
- Competitive Position
- 89/ 100
Competitive context
14 Active assets in the Recurrent Acute Myeloid Leukemia Due to Lineage Switch From B Acute Lymphoblastic Leukemia, KMT2A-Rearranged cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Revumenib National Cancer Institute (NCI) | Phase 2 | B |
Cytosin-Arabinosid National Cancer Institute (NCI) | Phase 2 | B |
Solu-Cortef Children's Oncology Group | Phase 2 | CCC |
Calaspargase Pegol Children's Oncology Group | Phase 2 | CCC |
VINCRISTINE SULFATE Children's Oncology Group | Phase 2 | CCC |
View all 14 →
Same molecule, other indications
Fludarabine is also rated in:
acute myeloid leukemia with abnormal bone marrow eosinophils inv(16)(p13q22) or t(16;16)(p13;q22)Dormant
BBB
Indicative ·
76 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →